-
Immunosuppressive CD29+ Treg accumulation in the liver in mice on checkpoint inhibitor therapy Gut (IF 24.5) Pub Date : 2023-09-28 Benjamin L Green, Yuta Myojin, Chi Ma, Benjamin Ruf, Lichun Ma, Qianfei Zhang, Umberto Rosato, Jonathan Qi, Mahler Revsine, Simon Wabitsch, Kylynda Bauer, Mohamed-Reda Benmebarek, Justin McCallen, Amran Nur, Xin Wang, Vivek Sehra, Revant Gupta, Manfred Claassen, Xin Wei Wang, Firouzeh Korangy, Tim F Greten
Objective Liver metastases are often resistant to immune checkpoint inhibitor therapy (ICI) and portend a worse prognosis compared with metastases to other locations. Regulatory T cells (Tregs) are one of several immunosuppressive cells implicated in ICI resistance of liver tumours, but the role played by Tregs residing within the liver surrounding a tumour is unknown. Design Flow cytometry and single-cell
-
UK and Ireland Joint Advisory Group (JAG) consensus statements for training and certification in diagnostic endoscopic ultrasound (EUS) Gut (IF 24.5) Pub Date : 2023-09-28 Tareq El Menabawey, Raymond McCrudden, Dushyant Shetty, Andrew D Hopper, Matthew T Huggett, Noor Bekkali, Nicholas R Carroll, Elaine Henry, Gavin J Johnson, Margaret G Keane, Mark Love, Colin J McKay, Sally Norton, Kofi Oppong, Ian Penman, Jayapal Ramesh, Barbara Ryan, Keith Siau, Manu Nayar
Background and aims International endoscopy societies vary in their approach for credentialing individuals in endoscopic ultrasound (EUS) to enable independent practice; however, there is no consensus in this or its implementation. In 2019, the Joint Advisory Group on GI Endoscopy (JAG) commissioned a working group to examine the evidence relating to this process for EUS. The aim of this was to develop
-
Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1/Kyn/AHR axis Gut (IF 24.5) Pub Date : 2023-09-28 Winnie Fong, Qing Li, Fenfen Ji, Wei Liang, Harry Cheuk Hay Lau, Xing Kang, Weixin Liu, Kenneth Kin-Wah To, Zhong Zuo, Xiaoxing Li, Xiang Zhang, Joseph JY Sung, Jun Yu
Objective Gut microbiota is a key player in dictating immunotherapy response. We aimed to explore the immunomodulatory effect of probiotic Lactobacillus gallinarum and its role in improving anti-programmed cell death protein 1 (PD1) efficacy against colorectal cancer (CRC). Design The effects of L. gallinarum in anti-PD1 response were assessed in syngeneic mouse models and azoxymethane/dextran sulfate
-
British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma Gut (IF 24.5) Pub Date : 2023-09-28 Simon M Rushbrook, Timothy James Kendall, Yoh Zen, Raneem Albazaz, Prakash Manoharan, Stephen P Pereira, Richard Sturgess, Brian R Davidson, Hassan Z Malik, Derek Manas, Nigel Heaton, K Raj Prasad, John Bridgewater, Juan W Valle, Rebecca Goody, Maria Hawkins, Wendy Prentice, Helen Morement, Martine Walmsley, Shahid A Khan
These guidelines for the diagnosis and management of cholangiocarcinoma (CCA) were commissioned by the British Society of Gastroenterology liver section. The guideline writing committee included a multidisciplinary team of experts from various specialties involved in the management of CCA, as well as patient/public representatives from AMMF (the Cholangiocarcinoma Charity) and PSC Support. Quality
-
FGF-21 analogues for treatment of non-alcoholic steatohepatitis and fibrosis: a meta-analysis with fragility index of phase 2 randomised placebo-controlled trials Gut (IF 24.5) Pub Date : 2023-09-27 Alessandro Mantovani, Herbert Tilg, Giovanni Targher
We have read with interest the excellent review by Trauner and Fuchs on the novel therapeutic approaches that are currently developed for treating non-alcoholic steatohepatitis (NASH).1 Although there are no licensed pharmacotherapies for NASH, long-acting fibroblast growth factor-21 (FGF-21) analogues are being evaluated to treat NASH because FGF-21 is a pleotropic liver-derived hormone regulating
-
Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy Gut (IF 24.5) Pub Date : 2023-09-27 Colm J O'Rourke, Massimiliano Salati, Colin Rae, Guido Carpino, Holly Leslie, Antonio Pea, Maria G Prete, Luca R Bonetti, Francesco Amato, Robert Montal, Rosie Upstill-Goddard, Colin Nixon, Paula Sanchon-Sanchez, Paolo Kunderfranco, Daniela Sia, Eugenio Gaudio, Diletta Overi, Stefano Cascinu, Dan Hogdall, Sian Pugh, Enric Domingo, John N Primrose, John Bridgewater, Andrea Spallanzani, Fabio Gelsomino
Objective Cytotoxic agents are the cornerstone of treatment for patients with advanced intrahepatic cholangiocarcinoma (iCCA), despite heterogeneous benefit. We hypothesised that the pretreatment molecular profiles of diagnostic biopsies can predict patient benefit from chemotherapy and define molecular bases of innate chemoresistance. Design We identified a cohort of advanced iCCA patients with comparable
-
Toning down the role of eosinophils in eosinophilic oesophagitis Gut (IF 24.5) Pub Date : 2023-09-26 Carlo Maria Rossi, Marco Vincenzo Lenti, Antonio Di Sabatino
Eosinophilic oesophagitis (EoE) is an immune-mediated disease of uncertain aetiology. The diagnosis of EoE relies on the epithelial infiltration of eosinophils (peak eosinophil count of ≥15 per high-power field (HPF)) and on the presence of symptoms. Consequently, a combined clinical–histological endpoint has been devised to assess response to treatments in clinical trials. Recent guidelines drafted
-
Vonoprazan-based versus proton pump inhibitor-based therapy in Helicobacter pylori eradication: an updated systematic review and meta-analysis of randomised trials Gut (IF 24.5) Pub Date : 2023-09-26 Po-Yueh Chen, Feng-Pai Tsai, Mei-Jyh Chen, Hsin-Yi Yang, Ming-Shiang Wu, Jyh-Ming Liou
We read the Maastricht VI/Florence consensus report published in GUT with great interest.1 The report suggested that vonoprazan-based therapy is superior, or not inferior, to conventional proton pump inhibitor (PPI)-based triple therapies for Helicobacter pylori eradication.1 However, the number of randomised controlled trials (RCTs) was small and the majority of previous trials were conducted in Japan
-
Antibiotic use and inflammatory bowel disease: number needed to harm? Authors’ reply Gut (IF 24.5) Pub Date : 2023-09-26 Adam S Faye, Tine Jess
We thank Ludvigsson for his interest in our work and for providing additional insights. As noted, our joint works implicate the role of antibiotics in the development of inflammatory bowel disease (IBD), however, there are limitations as well as unique strengths to our study design which should be noted.1 2 Although confounding may exist, our prospective cohort study design limits this possibility
-
Defining gene–lifestyle interactions in inflammatory bowel disease: progress towards understanding disease pathogenesis Gut (IF 24.5) Pub Date : 2023-09-26 Jianhui Zhao, Jie Chen, Yuhao Sun, Shuai Yuan, Judith Wellens, Rahul Kalla, Evropi Theodoratou, Xue Li, Jack Satsangi
Recently, Lopes et al quantified the effect of modifiable lifestyle factors in inflammatory bowel disease (IBD) prevention using population attributable risk, and reported that 42.9% of Crohn’s disease (CD) cases and 44.4% of ulcerative colitis (UC) cases could have been prevented by lifestyle interventions. This interesting result was based on 6 prospective cohorts including 3 US cohorts with 208
-
Epidemiology of Helicobacter in Chinese families: a foundation for cost-effective eradication strategies? Gut (IF 24.5) Pub Date : 2023-09-26 Barry Marshall
Your recent ‘Chinese Consensus Report on Family-based Helicobacter pylori infection Control and management (2021 Edition)’1 and ‘Large-scale, national, family-based epidemiological study on Helicobacter pylori infection in China: the time to change practice for related disease prevention’2 will encourage more doctors in China to consider Helicobacter pylori as a curable aetiology for gastrointestinal
-
Mixed-donor faecal microbiota transplantation was associated with increased butyrate-producing bacteria for obesity Gut (IF 24.5) Pub Date : 2023-09-26 Zhilu Xu, Joyce Wing Yan Mak, Yu Lin, Keli Yang, Qin Liu, Fen Zhang, Louis Lau, Whitney Tang, Jessica YL Ching, Hein M Tun, Paul Chan, Francis K L Chan, Siew C Ng
We read with interest the recent article by Haifer et al (Gut, 2022, 2022–3 27 742), which reported that donor gut microbiome stability and species evenness were associated with higher donor species engraftment in patients with UC following faecal microbiota transplantation (FMT). This has brought us one step closer towards the selection of optimal FMT donors. However, the high prevalence of extended‐spectrum
-
Wheat proteins as triggers of central nervous system inflammation Gut (IF 24.5) Pub Date : 2023-09-26 Alberto Caminero
The role of diet in the initiation and progression of disease is one of the most exciting areas of research nowadays. Although some recommendations begin to emerge in well-defined gastrointestinal conditions, food patterns associated with diseases of the central nervous system (CNS) such as multiple sclerosis (MS) are poorly understood. The study by Zevallos et al 1 shows that amylase trypsin inhibitors
-
Precancerous nature of intestinal metaplasia with increased chance of conversion and accelerated DNA methylation Gut (IF 24.5) Pub Date : 2023-09-26 Chihiro Takeuchi, Satoshi Yamashita, Yu-Yu Liu, Hideyuki Takeshima, Akiko Sasaki, Masahide Fukuda, Taiki Hashimoto, Tomoaki Naka, Kenichi Ishizu, Shigeki Sekine, Takaki Yoshikawa, Akinobu Hamada, Nobutake Yamamichi, Mitsuhiro Fujishiro, Toshikazu Ushijima
Objective The presence of intestinal metaplasia (IM) is a risk factor for gastric cancer. However, it is still controversial whether IM itself is precancerous or paracancerous. Here, we aimed to explore the precancerous nature of IM by analysing epigenetic alterations. Design Genome-wide DNA methylation analysis was conducted by EPIC BeadArray using IM crypts isolated by Alcian blue staining. Chromatin
-
Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study Gut (IF 24.5) Pub Date : 2023-09-22 Benjamin Douglas Liu, Sharon C Udemba, Katherine Liang, Yasir Tarabichi, Hannah Hill, Ronnie Fass, Gengqing Song
Background Shorter half-life glucagon-like peptide-1 receptor agonists (GLP-1 RAs) delay gastric emptying (DGE) more than GLP-1 RAs with longer half-lives. DGE is a known risk factor for gastro-oesophageal reflux disease (GERD) and its complications. Aim To determine whether short-acting or long-acting GLP-1 RAs are associated with an increased risk of new GERD or GERD-related complications Design
-
Interplay between diet, circulating indolepropionate concentrations and cardiometabolic health in US populations Gut (IF 24.5) Pub Date : 2023-09-22 Yang Hu, Jun Li, Biqi Wang, Lu Zhu, Yanping Li, Kerry L Ivey, Kyu Ha Lee, A Heather Eliassen, Andrew Chan, Curtis Huttenhower, Frank B Hu, Qibin Qi, Eric B Rimm, Qi Sun
Objectives To identify indolepropionate (IPA)-predicting gut microbiota species, investigate potential diet–microbiota interactions, and examine the prospective associations of circulating IPA concentrations with type 2 diabetes (T2D) and coronary heart disease (CHD) risk in free-living individuals. Design We included 287 men from the Men’s Lifestyle Validation Study, a substudy of the Health Professionals
-
Exploring the impact of gut microbial metabolites on inactivated SARS-CoV-2 vaccine efficacy during pregnancy and mother-to-infant antibody transfer Gut (IF 24.5) Pub Date : 2023-09-22 Xi Fu, Bingqian Du, Pei-An Chen, Aga Shama, Baolan Chen, Xi Zhang, Xue Han, Yingxia Xu, Yajie Gong, Xia Zeng, Chongzhen Sun, Wenhan Yang, Xiaohui Xing, Zhongjun Li, Yanyan Fu, Dongyun Ke, Niping Wang, Yun Xia, Yu Sun, Qingsong Chen
The recent publication by Ng et al titled ‘Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events’ provides valuable insights on gut microbiota in modulating immune responses to both inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccines. The authors identified specific gut microbiota markers influenced immunity and vaccine efficacy, suggesting that
-
Smart capsules for sensing and sampling the gut: status, challenges and prospects Gut (IF 24.5) Pub Date : 2023-09-21 Muhammad Rehan, Ibrahim Al-Bahadly, David G Thomas, Wayne Young, Leo K Cheng, Ebubekir Avci
Smart capsules are developing at a tremendous pace with a promise to become effective clinical tools for the diagnosis and monitoring of gut health. This field emerged in the early 2000s with a successful translation of an endoscopic capsule from laboratory prototype to a commercially viable clinical device. Recently, this field has accelerated and expanded into various domains beyond imaging, including
-
Reflux conditions induce E-cadherin cleavage and EMT via APE1 redox function in oesophageal adenocarcinoma Gut (IF 24.5) Pub Date : 2023-09-21 Heng Lu, Long Long Cao, Farah Ballout, Abbes Belkhiri, DunFa Peng, Lei Chen, Zheng Chen, Mohammed Soutto, Timothy C Wang, Jianwen Que, Silvia Giordano, Mary Kay Washington, Steven Chen, Oliver Gene McDonald, Alexander Zaika, Wael El-Rifai
Objective Chronic gastro-oesophageal reflux disease, where acidic bile salts (ABS) reflux into the oesophagus, is the leading risk factor for oesophageal adenocarcinoma (EAC). We investigated the role of ABS in promoting epithelial-mesenchymal transition (EMT) in EAC. Design RNA sequencing data and public databases were analysed for the EMT pathway enrichment and patients’ relapse-free survival. Cell
-
Updates to the modern diagnosis of GERD: Lyon consensus 2.0 Gut (IF 24.5) Pub Date : 2023-09-21 C Prakash Gyawali, Rena Yadlapati, Ronnie Fass, David Katzka, John Pandolfino, Edoardo Savarino, Daniel Sifrim, Stuart Spechler, Frank Zerbib, Mark R Fox, Shobna Bhatia, Nicola de Bortoli, Yu Kyung Cho, Daniel Cisternas, Chien-Lin Chen, Charles Cock, Albis Hani, Jose Maria Remes Troche, Yinglian Xiao, Michael F Vaezi, Sabine Roman
The Lyon Consensus provides conclusive criteria for and against the diagnosis of gastro-oesophageal reflux disease (GERD), and adjunctive metrics that consolidate or refute GERD diagnosis when primary criteria are borderline or inconclusive. An international core and working group was assembled to evaluate research since publication of the original Lyon Consensus, and to vote on statements collaboratively
-
Disruption of CerS6-mediated sphingolipid metabolism by FTO deficiency aggravates ulcerative colitis Gut (IF 24.5) Pub Date : 2023-09-21 Yanru Ma, Xinyu Zhang, Baoqin Xuan, Danjie Li, Nan Yin, Lijun Ning, Yi-Lu Zhou, Yuqing Yan, Tianying Tong, Xiaoqiang Zhu, Xiaowen Huang, Muni Hu, Zhenhua Wang, Zhe Cui, Huabin Li, Jiqiu Wang, Jing-Yuan Fang, Ruixin Liu, Haoyan Chen, Jie Hong
Background and aims Deregulation of RNA N6-methyladenosine (m6A) modification in intestinal epithelial cells (IECs) influences intestinal immune cells and leads to intestinal inflammation. We studied the function of fat mass-and obesity-associated protein (FTO), one of the m6A demethylases, in patients with ulcerative colitis (UC). Methods We analysed colon tissues of Ftoflox/flox; Villin-cre mice
-
Optimal measurement of gastric emptying of solids in gastroparesis or functional dyspepsia: evidence to establish standard test Gut (IF 24.5) Pub Date : 2023-09-19 Michael Camilleri, Ting Zheng, Kia Vosoughi, Camille Lupianez-Merly, Deborah Eckert, Irene Busciglio, Duane Burton, Saam Dilmaghani
Objective Symptoms in gastroparesis (Gp) and functional dyspepsia (FD) overlap; using egg protein substitute to measure gastric emptying of solids (GES), ~40% of patients are reclassified from Gp to FD, and vice versa. Our aim was to assess inter-individual and intra-individual coefficients of variation (COV) in GES in symptomatic patients with Gp or FD with documented slow or normal GES, respectively
-
Key metabolomic alterations are associated with ulcerative colitis disease state and activity: a validation analysis Gut (IF 24.5) Pub Date : 2023-09-14 John David Chetwood, Sudarshan Paramsothy, Craig Haifer, Thomas J Borody, Michael A Kamm, Rupert W Leong, Nadeem O Kaakoush
We read with interest the recent paper by Vich Vila et al , which discussed alterations in the metabolome of patients with inflammatory bowel disease (IBD).1 Here, the authors described >300 molecules that were differentially abundant in the faeces of 424 patients with IBD compared with 255 healthy controls, analysed with liquid chromatography with tandem mass spectrometry as well as genome-wide association
-
Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer Gut (IF 24.5) Pub Date : 2023-09-14 Casper W F van Eijck, Dana A M Mustafa, Disha Vadgama, Noel F C C de Miranda, Bas Groot Koerkamp, Geertjan van Tienhoven, Sjoerd H van der Burg, Núria Malats, Casper H J van Eijck
Background This study investigates sex disparities in clinical outcomes and tumour immune profiles in patients with pancreatic ductal adenocarcinoma (PDAC) who underwent upfront resection or resection preceded by gemcitabine-based neoadjuvant chemoradiotherapy (nCRT). Methods Patients originated from the PREOPANC randomised controlled trial. Upfront surgery was performed in 82 patients, and 66 received
-
Comparing the relative efficacy of therapeutics for eosinophilic oesophagitis: is counting eosinophils the right target? Gut (IF 24.5) Pub Date : 2023-09-14 Ikuo Hirano, David Katzka
Eosinophilic oesophagitis (EoE) is characterised by an abundance of oesophageal epithelial eosinophils.1 There is strong rationale that supports the eosinophil as central to the pathophysiology of EoE. In histology, the eosinophil is numerically the dominant inflammatory cell. Moreover, the eosinophil is capable of producing inflammation and tissue remodelling in human tissue. On degranulation, multiple
-
DNA-methylation signature accurately differentiates pancreatic cancer from chronic pancreatitis in tissue and plasma Gut (IF 24.5) Pub Date : 2023-09-14 Yenan Wu, Isabelle Seufert, Fawaz N Al-Shaheri, Roman Kurilov, Andrea S Bauer, Mehdi Manoochehri, Evgeny A Moskalev, Benedikt Brors, Christin Tjaden, Nathalia A Giese, Thilo Hackert, Markus W Büchler, Jörg D Hoheisel
Objective Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy. Differentiation from chronic pancreatitis (CP) is currently inaccurate in about one-third of cases. Misdiagnoses in both directions, however, have severe consequences for patients. We set out to identify molecular markers for a clear distinction between PDAC and CP. Design Genome-wide variations of DNA-methylation, messenger
-
Tailoring treatment to the circumstance: reasoning behind metal versus plastic drainage of pancreatic collections – authors’ reply Gut (IF 24.5) Pub Date : 2023-09-12 John Gásdal Karstensen, Srdan Novovic, Palle Nordblad Schmidt
We thank Vanella et al for their interest in our paper and for pointing out additional details and perspectives.1 2 In our study, we randomised patients with large pancreatic walled-off necrosis (WON) and a need for transgastric drainage to either a 20 mm lumen apposing metal stent (LAMS) or double pigtail stent (DPT) and found no superiority of the LAMS in terms of number of necrosectomies, clinical
-
BSG guidelines on faecal immunochemical testing: are they ‘FIT’ for purpose? Gut (IF 24.5) Pub Date : 2023-10-01 Colin J Rees, Willie Hamilton
The use of faecal immunochemical testing (FIT) for patients with features of possible colorectal cancer (CRC) has increased significantly over recent years. The UK has been slower to adopt FIT than several other countries, especially in Scandinavia.1 Colonoscopy remains the ‘gold-standard’ test with high sensitivity and specificity, and allows biopsy of lesions and removal of polyps. However, endoscopy
-
Multiple inflammatory mechanisms in eosinophilic oesophagitis make it unlikely that single pathway inhibition by monoclonal biological therapies would succeed Gut (IF 24.5) Pub Date : 2023-10-01 Stephen E Attwood
Once regarded as a rare disease, the incidence and prevalence of eosinophilic oesophagitis (EoE) have risen consistently over the past 25 years.1 It is now the second most common disease of the oesophagus after gastro-oesophageal reflux disease, and the most likely cause of thoracic dysphagia and of food bolus obstruction presenting to emergency departments.2 With the burden ever growing, it behoves
-
Is HBx protein the X factor in the pathogenesis of IBD? Gut (IF 24.5) Pub Date : 2023-10-01 Indrani Mukhopadhya
The role of viruses in the aetiopathogenesis of inflammatory bowel disease (IBD) has been a topic of conjecture for decades. Initial focus on specific viral agents in IBD like norovirus, rotaviruses and measles virus did not gain ground. The advent of metagenomics and detailed assessment of the ‘whole gut virome’ has now shown that the gastrointestinal tract harbours nearly 109 virus like particles
-
Obesity promotes a leaky gut, inflammation and pre-diabetes by lowering gut microbiota that metabolise ethanolamine Gut (IF 24.5) Pub Date : 2023-10-01 Han Fang, Rodrigo R e-Lacerda, Jonathan D Schertzer
Microbiota are a source of low-grade inflammation during obesity and contribute to insulin resistance and poor blood glucose control among other mechanisms in the progression of type 2 diabetes.1 Nearly all bacteria that reside within the host are found in the intestine, but it is not yet clear how microbiota are a source of inflammation in the circulation or metabolic tissues during obesity. A key
-
MicroRNA-223: a key regulator of liver tumour microenvironment Gut (IF 24.5) Pub Date : 2023-10-01 Matias A Avila
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths worldwide with few effective drug treatments. Recent combination therapies inhibiting immune checkpoints and angiogenesis showed better overall and progression-free survival outcomes than the protein kinase inhibitor sorafenib in patients with unresectable HCC,1 suggesting targeting tumour microenvironment (TME) is
-
New insights into an old paradigm: why IgA accumulates in alcoholic liver disease and what could be its role Gut (IF 24.5) Pub Date : 2023-10-01 Dragos Ciocan, Williams Turpin
Alcoholic liver disease (ALD) is the most prevalent cause of chronic liver disease in western countries with highly morbid complications, such as alcohol-associated hepatitis and limited therapeutic options.1 The pathogenesis of ALD is highly influenced by the gut-liver axis1 and some of the key features of ALD include dysbiosis (bacterial, fungal and viral), increased intestinal permeability and translocation
-
Enolase: a metabolic checkpoint behind diverse exhaustion stages of CD8+ T cells in chronic HBV and HCV Gut (IF 24.5) Pub Date : 2023-10-01 Nina Le Bert, Paola Fisicaro
Resolving chronic hepatic infections caused by hepatitis B and C viruses (HBV and HCV) could be realised through two primary approaches: direct targeting of the virus or enhancement of the immune response, encompassing antiviral and immune-based therapies, respectively. Although direct-acting antiviral (DAA) medications exhibit remarkable efficacy in curing chronic HCV infection, the current approach
-
Assessment of the yearly carbon emission of a gastrointestinal endoscopy unit Gut (IF 24.5) Pub Date : 2023-10-01 Dorothea Henniger, Max Windsheimer, Hans Beck, Markus Brand, Thomas Lux, Alexander Hann, Alexander Meining
Despite ‘green endoscopy’ has meanwhile been regarded as a highly relevant topic, the scientific basis of ongoing discussions and various position statements is poor. We developed a tool for calculating the yearly emissions of a middle-sized gastrointestinal (GI) endoscopy unit in Germany (8000 procedures per year). Calculation was based on in-house energy consumption as well as emissions caused by
-
Psychological symptoms do not discriminate between reflux phenotypes along the organic-functional refractory GERD spectrum Gut (IF 24.5) Pub Date : 2023-10-01 Annelies Geeraerts, Livia Guadagnoli, Ans Pauwels, Hannelore Geysen, Thomas Neyens, Lukas Van Oudenhove, Tim Vanuytsel, Jan Tack
Objective Historically, psychological processes are associated with disorders at the functional end of the gastro-oesophageal reflux disease (GERD) spectrum. However, recent research suggests that psychological symptoms are relevant across the entire GERD spectrum. We aim to investigate whether psychological symptoms are associated with reflux phenotype (True GERD, Borderline GERD, reflux hypersensitivity
-
Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial Gut (IF 24.5) Pub Date : 2023-10-01 Evan S Dellon, Kathryn A Peterson, Benjamin L Mitlyng, Alina Iuga, Christine E Bookhout, Lindsay M Cortright, Kacie B Walker, Timothy S Gee, Sarah J McGee, Brenderia A Cameron, Joseph A Galanko, John T Woosley, Swathi Eluri, Susan E Moist, Ikuo Hirano
Objective We aimed to determine whether mepolizumab, an anti-IL-5 antibody, was more effective than placebo for improving dysphagia symptoms and decreasing oesophageal eosinophil counts in eosinophilic oesophagitis (EoE). Methods We conducted a multicentre, randomised, double-blind, placebo-controlled, trial. In the first part, patients aged 16–75 with EoE and dysphagia symptoms (per EoE Symptom Activity
-
Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo Gut (IF 24.5) Pub Date : 2023-10-01 Luca Massimino, Orazio Palmieri, Amanda Facoetti, Davide Fuggetta, Salvatore Spanò, Luigi Antonio Lamparelli, Silvia D'Alessio, Stefania Cagliani, Federica Furfaro, Ferdinando D'Amico, Alessandra Zilli, Gionata Fiorino, Tommaso Lorenzo Parigi, Daniele Noviello, Anna Latiano, Fabrizio Bossa, Tiziana Latiano, Alessandra Pirola, Luca Mologni, Rocco Giovanni Piazza, Danilo Abbati, Francesco Perri, Chiara
Objectives Ulcerative colitis (UC) is a chronic inflammatory disorder of unknown aetiology. Gut virome dysbiosis is fundamental in UC progression, although its role in the early phases of the disease is far from fully understood. Therefore, we sought to investigate the role of a virome-associated protein encoded by the Orthohepadnavirus genus, the hepatitis B virus X protein (HBx), in UC aetiopathogenesis
-
A mechanism by which gut microbiota elevates permeability and inflammation in obese/diabetic mice and human gut Gut (IF 24.5) Pub Date : 2023-10-01 Sidharth P Mishra, Bo Wang, Shalini Jain, Jingzhong Ding, Jared Rejeski, Cristina M Furdui, Dalane W Kitzman, Subhash Taraphder, Christian Brechot, Ambuj Kumar, Hariom Yadav
Objective Ample evidence exists for the role of abnormal gut microbiota composition and increased gut permeability (‘leaky gut’) in chronic inflammation that commonly co-occurs in the gut in both obesity and diabetes, yet the detailed mechanisms involved in this process have remained elusive. Design In this study, we substantiate the causal role of the gut microbiota by use of faecal conditioned media
-
Technical performance and diagnostic yield of motorised spiral enteroscopy compared with single-balloon enteroscopy in suspected Crohn’s disease: a randomised controlled, open-label study (the MOTOR-CD trial) Gut (IF 24.5) Pub Date : 2023-10-01 Partha Pal, Mohan Ramchandani, Rupa Banerjee, Piyush Viswakarma, Aniruddha Pratap Singh, Manohar Reddy, Hardik Rughwani, Rajendra Patel, Anuradha Sekaran, Swathi Kanaganti, Santosh Darisetty, Zaheer Nabi, Jagadish Singh, Rajesh Gupta, Sundeep Lakhtakia, Rebala Pradeep, G Venkat Rao, Manu Tandan, D Nageshwar Reddy
Objective Recent studies have shown that motorised spiral enteroscopy (MSE) enables deeper and total small bowel evaluation compared with single-balloon enteroscopy (SBE) in suspected Crohn’s disease (CD) when analysed per procedure. However, no randomised controlled study has compared bidirectional MSE with bidirectional SBE in suspected CD. Design Patients with suspected CD requiring small bowel
-
Treatment of adenoma recurrence after endoscopic mucosal resection Gut (IF 24.5) Pub Date : 2023-10-01 David J Tate, Lobke Desomer, Maria Eva Argenziano, Neha Mahajan, Mayenaaz Sidhu, Sergei Vosko, Neal Shahidi, Eric Lee, Stephen J Williams, Nicholas G Burgess, Michael J Bourke
Objective Residual or recurrent adenoma (RRA) after endoscopic mucosal resection (EMR) of large non-pedunculated colorectal polyps (LNPCPs) of ≥20 mm is a major limitation. Data on outcomes of the endoscopic treatment of recurrence are scarce, and no evidence-based standard exists. We investigated the efficacy of endoscopic retreatment over time in a large prospective cohort. Design Over 139 months
-
Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells Gut (IF 24.5) Pub Date : 2023-10-01 Alessia Potenza, Chiara Balestrieri, Martina Spiga, Luca Albarello, Federica Pedica, Francesco Manfredi, Beatrice Claudia Cianciotti, Claudia De Lalla, Oronza A Botrugno, Cristina Faccani, Lorena Stasi, Elena Tassi, Silvia Bonfiglio, Giulia Maria Scotti, Miriam Redegalli, Donatella Biancolini, Barbara Camisa, Elena Tiziano, Camilla Sirini, Monica Casucci, Chiara Iozzi, Danilo Abbati, Fabio Simeoni
Objective Colorectal tumours are often densely infiltrated by immune cells that have a role in surveillance and modulation of tumour progression but are burdened by immunosuppressive signals, which might vary from primary to metastatic stages. Here, we deployed a multidimensional approach to unravel the T-cell functional landscape in primary colorectal cancers (CRC) and liver metastases, and genome
-
An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles Gut (IF 24.5) Pub Date : 2023-10-01 Robert S Bresalier, Carlo Senore, Graeme P Young, James Allison, Robert Benamouzig, Sally Benton, Patrick M M Bossuyt, Luis Caro, Beatriz Carvalho, Han-Mo Chiu, Veerle M H Coupé, Willemijn de Klaver, Clasine Maria de Klerk, Evelien Dekker, Sunil Dolwani, Callum G Fraser, William Grady, Lydia Guittet, Samir Gupta, Stephen P Halloran, Ulrike Haug, Geir Hoff, Steven Itzkowitz, Tim Kortlever, Anastasios
Objective New screening tests for colorectal cancer (CRC) are rapidly emerging. Conducting trials with mortality reduction as the end point supporting their adoption is challenging. We re-examined the principles underlying evaluation of new non-invasive tests in view of technological developments and identification of new biomarkers. Design A formal consensus approach involving a multidisciplinary
-
Consensus definition of sludge and microlithiasis as a possible cause of pancreatitis Gut (IF 24.5) Pub Date : 2023-10-01 Michal Żorniak, Simon Sirtl, Georg Beyer, Ujjwal Mukund Mahajan, Katharina Bretthauer, Jörg Schirra, Christian Schulz, Thomas Kohlmann, Markus M Lerch, Julia Mayerle
Objective In up to 20% of patients, the aetiology of acute pancreatitis (AP) remains elusive and is thus called idiopathic. On more detailed review these cases can often be explained through biliary disease and are amenable to treatment. Findings range from biliary sludge to microlithiasis but their definitions remain fluid and controversial. Design A systematic literature review (1682 reports, following
-
Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas Gut (IF 24.5) Pub Date : 2023-10-01 Gabriela Sarti Kinker, Glauco Akelinghton Freire Vitiello, Ariane Barros Diniz, Mariela Pires Cabral-Piccin, Pedro Henrique Barbosa Pereira, Maria Letícia Rodrigues Carvalho, Wallax Augusto Silva Ferreira, Alexandre Silva Chaves, Amanda Rondinelli, Arianne Fagotti Gusmão, Alexandre Defelicibus, Gabriel Oliveira dos Santos, Warley Abreu Nunes, Laura Carolina López Claro, Talita Magalhães Bernardo, Ricardo
Objective To better understand the immune microenvironment of pancreatic ductal adenocarcinomas (PDACs), here we explored the relevance of T and B cell compartmentalisation into tertiary lymphoid structures (TLSs) for the generation of local antitumour immunity. Design We characterised the functional states and spatial organisation of PDAC-infiltrating T and B cells using single-cell RNA sequencing
-
MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression Gut (IF 24.5) Pub Date : 2023-10-01 Yaojie Fu, Bryan Mackowiak, Dechun Feng, Hongkun Lu, Yukun Guan, Taylor Lehner, Hongna Pan, Xin Wei Wang, Yong He, Bin Gao
Objective The current treatment for hepatocellular carcinoma (HCC) to block angiogenesis and immunosuppression provides some benefits only for a subset of patients with HCC, thus optimised therapeutic regimens are unmet needs, which require a thorough understanding of the underlying mechanisms by which tumour cells orchestrate an inflamed tumour microenvironment with significant myeloid cell infiltration
-
Hepatic pIgR-mediated secretion of IgA limits bacterial translocation and prevents ethanol-induced liver disease in mice Gut (IF 24.5) Pub Date : 2023-10-01 Tim Hendrikx, Sonja Lang, Dragana Rajcic, Yanhan Wang, Sara McArdle, Kenneth Kim, Zbigniew Mikulski, Bernd Schnabl
Objective Alcohol-associated liver disease is accompanied by microbial dysbiosis, increased intestinal permeability and hepatic exposure to translocated microbial products that contribute to disease progression. A key strategy to generate immune protection against invading pathogens is the secretion of IgA in the gut. Intestinal IgA levels depend on the polymeric immunoglobulin receptor (pIgR), which
-
Enolase represents a metabolic checkpoint controlling the differential exhaustion programmes of hepatitis virus-specific CD8+ T cells Gut (IF 24.5) Pub Date : 2023-10-01 Frances Winkler, Anna V Hipp, Carlos Ramirez, Bianca Martin, Matteo Villa, Emilia Neuwirt, Oliver Gorka, Jeroen Aerssens, Susanne E Johansson, Nisha Rana, Sian Llewellyn-Lacey, David A Price, Marcus Panning, Olaf Groß, Erika L Pearce, Carl M Hermann, Kathrin Schumann, Luciana Hannibal, Christoph Neumann-Haefelin, Tobias Boettler, Percy Knolle, Maike Hofmann, Dirk Wohlleber, Robert Thimme, Bertram Bengsch
Objective Exhausted T cells with limited effector function are enriched in chronic hepatitis B and C virus (HBV and HCV) infection. Metabolic regulation contributes to exhaustion, but it remains unclear how metabolism relates to different exhaustion states, is impacted by antiviral therapy, and if metabolic checkpoints regulate dysfunction. Design Metabolic state, exhaustion and transcriptome of virus-specific
-
Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease Gut (IF 24.5) Pub Date : 2023-10-01 Nanne K H de Boer, Melek Simsek, Berrie Meijer, Markus F Neurath, Ad van Bodegraven, Chris J J Mulder
Drug rediscovery refers to the principle of using ‘old’ drugs outside the indications mentioned in the summary of product characteristics. In the past decades, several drugs were rediscovered in a wide variety of medical fields. One of the most recent examples is the unconditional registration of thioguanine (TG), a thiopurine derivative, in patients with inflammatory bowel disease in the Netherlands
-
SARS-CoV-2 Omicron variant infection was associated with higher morbidity in patients with cirrhosis Gut (IF 24.5) Pub Date : 2023-10-01 Anand V Kulkarni, Chandan S Metage, Baqar Ali Gora, Sowmya Tirumalle, Kalyan Rakam, Anveshi Satyavadi, Mithun Sharma, Sameer Shaik, Deepika Gujjarlapudi, Padaki Nagaraja Rao, D Nageshwar Reddy
Dufour et al highlighted that the effect of COVID-19 in patients with cirrhosis is derived from the prevaccination era and suggested that the impact of Omicron infection in patients with cirrhosis needs to be elucidated.1 We agree with the author that previous studies have reported significant morbidity and mortality in patients with cirrhosis infected with SARS CoV-2 in the prevaccination era.2–7
-
Dynamic changes in host immune system and gut microbiota are associated with the production of SARS-CoV-2 antibodies Gut (IF 24.5) Pub Date : 2023-10-01 Maozhen Han, Yixuan Huang, Hongya Gui, Yixuan Xiao, Maozhang He, Jiling Liu, Xiujing Cao, Meijuan Zheng, Min Lu, Weihua Jia, Hui Li, Xiaoyan Wang, Na Zhang, Shu-an Kong, Xiaohui Liu, Yonggui Wu, Fengchang Wu, Shenghai Huang
Recently, we read the article by Ng et al with great interest,1 which identified several gut microbiota harbour the potential to improve immune response and reduce adverse events following COVID-19 vaccines, and demonstrated that gut microbiota has the potential to complement the effectiveness of vaccines. Together with several recent studies, gut microbiota plays a key role in modulating immune responses
-
Gut microbiota as non-invasive diagnostic and prognostic biomarkers for natural killer/T-cell lymphoma Gut (IF 24.5) Pub Date : 2023-10-01 Zhuangzhuang Shi, Guoru Hu, Min W Li, Lei Zhang, Xin Li, Ling Li, Xinhua Wang, Xiaorui Fu, Zhenchang Sun, Xudong Zhang, Li Tian, Zhaoming Li, Wei-Hua Chen, Mingzhi Zhang
We read with interest the study by Kartal et al 1 showing that the gut-microbiota-derived biomarkers for disease stratification are often shared by subjects across disease cohorts. Here, we confirmed their observations with findings from a newly diagnosed natural killer/T-cell lymphoma (NKTCL) cohort, in which the gut biomarkers were significantly overlapped with those of multiple disease cohorts and
-
Response to letter to the editor: lumen-apposing metal stents versus double-pigtail plastic stents for infected necrotising pancreatitis Gut (IF 24.5) Pub Date : 2023-10-01 Lotte Boxhoorn, Robert C Verdonk, Rogier P Voermans
We kindly thank Larghi et al and Tiwari et al for their interest in our study.1–3 We acknowledge the limitations of our study. However, we would like to make some additional remarks. We agree with the authors that our approach inherits the risk of selection bias, given the non-randomised comparative design and baseline differences between groups. Being aware of this, we corrected for baseline imbalances
-
Response to Mansoor et al: ‘epidemiology of inflammatory bowel disease in men with high-risk homosexual activity’ Gut (IF 24.5) Pub Date : 2023-10-01 Kira L Newman, Kara Jencks, Victor Chedid, Sonali Paul, Peter D R Higgins, Sunanda V Kane, Millie Long
We were interested to read the letter by Mansoor et al , ‘epidemiology of inflammatory bowel disease (IBD) in men with high-risk homosexual activity’,1 which was in response to the two recently published studies by Agrawal et al 2 and Cha et al .3 However, we would like to point out significant methodological flaws in their design and analysis. The data used have the potential to misclassify both the
-
Overcoming regional limitations: transfer learning for cross-regional microbial-based diagnosis of diseases Gut (IF 24.5) Pub Date : 2023-10-01 Nan Wang, Mingyue Cheng, Kang Ning
With great interest, we have read the article by Clooney et al , which highlighted the regional effects on the heterogeneity of the gut microbiota among populations with inflammatory bowel disease (IBD).1 As a result, regional effects would largely limit the microbial-based diagnosis of diseases across regions. Although current machine learning methods based on microbial features have been applied
-
Bad gut feeling: a case of recurrent abdominal pain in a young man Gut (IF 24.5) Pub Date : 2023-10-01 Stela Celaj, Harkirat Singh
A Southeast Asian man in his early 20s with no medical history presented with persistent abdominal pain and nausea for 3 weeks. He reported no recent sick contacts and no travel in the past 5 years since arrival to the USA. Physical examination was notable for right lower quadrant tenderness. CT of the abdomen and pelvis showed hyperaemia and fat stranding near the terminal ileum and cecum, concerning
-
Correction: P150 Adult menetrier’s disease: a clinical profile and systematic review of published cases Gut (IF 24.5) Pub Date : 2023-10-01 BMJ Publishing Group Ltd and British Society of Gastroenterology
Stone J, Funk C, Moin K, et al . P150 Adult menetrier’s …
-
Predicting residual neoplasia after a non-curative gastric ESD: validation and modification of the eCura system in the Western setting: the W-eCura score Gut (IF 24.5) Pub Date : 2023-09-04 Rui Morais, Diogo Libanio, Mario Dinis Ribeiro, Aníbal Ferreira, Pedro Barreiro, Michael J Bourke, Sunil Gupta, Pedro Amaro, Ricardo Küttner Magalhães, Paolo Cecinato, Pedro Boal Carvalho, Rolando Pinho, Enrique Rodríguez de Santiago, Sandro Sferrazza, Arnaud Lemmers, Mariana Figueiredo, Marhieu Pioche, Francisco Gallego, Eduardo Albéniz, Felipe Ramos Zabala, Hugo Uchima, Frieder Berr, Andrej Wagner
Objective To evaluate the risk factors for lymph node metastasis (LNM) after a non-curative (NC) gastric endoscopic submucosal dissection (ESD) and to validate and eventually refine the eCura scoring system in the Western setting. Also, to assess the rate and risk factors for parietal residual disease. Design Retrospective multicentre multinational study of prospectively collected registries from 19
-
Abnormal gastrointestinal motility is a major factor in explaining symptoms and a potential therapeutic target in patients with disorders of gut–brain interaction Gut (IF 24.5) Pub Date : 2023-09-04 Michael Camilleri
The objective of this article is to review the evidence of abnormal gastrointestinal (GI) tract motor functions in the context of disorders of gut–brain interaction (DGBI). These include abnormalities of oesophageal motility, gastric emptying, gastric accommodation, colonic transit, colonic motility, colonic volume and rectal evacuation. For each section regarding GI motor dysfunction, the article
-
Endoluminal radiofrequency ablation in patients with malignant biliary obstruction: a randomised trial Gut (IF 24.5) Pub Date : 2023-08-31 Jana Jarosova, Lea Zarivnijova, Ivana Cibulkova, Jan Mares, Peter Macinga, Alzbeta Hujova, Premysl Falt, Ondrej Urban, Jan Hajer, Julius Spicak, Tomas Hucl
Background Endoluminal radiofrequency ablation (RFA) has been promoted as palliative treatment for patients with cholangiocarcinoma (CCA) and pancreatic ductal adenocarcinoma (PDAC) in order to improve biliary drainage and eventually prolong survival. No high level evidence is, however, available on this technique. Design In this randomised controlled study, we compared endoluminal RFA plus stenting